# OrigiMed

Source: https://onco.cc/companies/origimed/  
OnCo record `origimed` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Shanghai cancer genomics company whose OriMIRACLE S blood test tracks a tumour's shared mutations to look for leftover cancer.

## Summary

OrigiMed is a Shanghai genomics company. Its employees co-authored the development of OriMIRACLE S, a tumour-informed residual disease test using clonal variants chosen by its OriSelector algorithm (Cancer Medicine 2023), and the whole-exome sequencing behind a 2024 osteosarcoma ctDNA study at Sun Yat-sen University (eClinicalMedicine 2024).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- HQ: Shanghai
- Type: diagnostics

## Sources

- Qi et al., OriMIRACLE S (Cancer Medicine 2023): https://doi.org/10.1002/cam4.6286

## Connected records

- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/)
- key papers: [Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay](https://onco.cc/key-papers/paper-qi-orimiracle-gastrointestinal-cancer-med-2023/), [Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma](https://onco.cc/key-papers/paper-fu-osteosarcoma-ctdna-eclinicalmedicine-2024/)
- drugs: [OriMIRACLE S](https://onco.cc/drugs/orimiracle-s/)

---
JSON: https://onco.cc/api/v1/entities/origimed.json